Literature DB >> 15016085

Orexin (hypocretin)/dynorphin neurons control GABAergic inputs to tuberomammillary neurons.

Krister S Eriksson1, Olga A Sergeeva, Oliver Selbach, Helmut L Haas.   

Abstract

High activity of the histaminergic neurons in the tuberomammillary (TM) nucleus increases wakefulness, and their firing rate is highest during waking and lowest during rapid eye movement sleep. The TM neurons receive a prominent innervation from sleep-active gamma-aminobutyric acidergic (GABAergic) neurons in the ventrolateral preoptic nucleus, which inhibits them during sleep. They also receive an excitatory input from the orexin- and dynorphin-containing neurons in the lateral hypothalamus, which are critically involved in sleep regulation and whose dysfunction causes narcolepsy. We have used intracellular recordings and immunohistochemistry to study if orexin neurons exert control over the GABAergic inputs to TM neurons in rat hypothalamic slices. Dynorphin suppressed GABAergic inputs and thus disinhibits the TM neurons, acting in concert with orexin to increase the excitability of these neurons. In contrast, both orexin-A and orexin-B markedly increased the frequency of GABAergic potentials, while co-application of orexin and dynorphin produced responses similar to dynorphin alone. Thus, orexins excite TM neurons directly and by disinhibition, gated by dynorphin. These data might explain some of the neuropathology of narcolepsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016085     DOI: 10.1111/j.1460-9568.2004.03243.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  32 in total

Review 1.  Hypothalamic control of sleep in aging.

Authors:  Asya Rolls
Journal:  Neuromolecular Med       Date:  2012-03-09       Impact factor: 3.843

Review 2.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

3.  Modafinil in sports: ethical considerations.

Authors:  K R Kaufman
Journal:  Br J Sports Med       Date:  2005-04       Impact factor: 13.800

4.  What optogenetic stimulation is telling us (and failing to tell us) about fast neurotransmitters and neuromodulators in brain circuits for wake-sleep regulation.

Authors:  Elda Arrigoni; Clifford B Saper
Journal:  Curr Opin Neurobiol       Date:  2014-07-26       Impact factor: 6.627

Review 5.  Ventromedial hypothalamus glucose-inhibited neurones: A role in glucose and energy homeostasis?

Authors:  Pamela R Hirschberg; Pallabi Sarkar; Suraj B Teegala; Vanessa H Routh
Journal:  J Neuroendocrinol       Date:  2019-08-04       Impact factor: 3.627

Review 6.  Pontine reticular formation (PnO) administration of hypocretin-1 increases PnO GABA levels and wakefulness.

Authors:  Christopher J Watson; Haideliza Soto-Calderon; Ralph Lydic; Helen A Baghdoyan
Journal:  Sleep       Date:  2008-04       Impact factor: 5.849

7.  The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems.

Authors:  Gregory S Parks; Deepti R Warrier; Lars Dittrich; Michael D Schwartz; Jeremiah B Palmerston; Thomas C Neylan; Stephen R Morairty; Thomas S Kilduff
Journal:  Neuropsychopharmacology       Date:  2015-08-20       Impact factor: 7.853

8.  Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone.

Authors:  Regis Parmentier; Sergej Kolbaev; Boris P Klyuch; David Vandael; Jian-Sheng Lin; Oliver Selbach; Helmut L Haas; Olga A Sergeeva
Journal:  J Neurosci       Date:  2009-04-08       Impact factor: 6.167

Review 9.  Cluster headache, hypothalamus, and orexin.

Authors:  Philip R Holland; Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2009-04

10.  Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis.

Authors:  A Nuñez; M L Rodrigo-Angulo; I De Andrés; M Garzón
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.